NeoDynamics AB (publ) approved for listing on Spotlight Stock Market

NeoDynamics AB (publ) (”NeoDynamics”) – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – today announces that the company has been approved for listing at Spotlight Stock Market (”Spotlight”). The approval is given under the condition that the company raises the minimum limit and provided that Spotlight’s ownership requirements are met. NeoDynamics also announces that the subscription period in the upcoming issue of units will commence on Wednesday the 31st of October and conclude on the 14th of November 2018. A fully subscribed issue of units will initially provide the company with approximately SEK 50.5 million before issue costs and a further SEK 25.3 million in case all of the attached free series TO 1 warrants are exercised. NeoDynamics has secured approximately 70 percent of the planned issue amount thought subscription commitments and a gratuitous guarantee subscription. The company’s principal shareholder is also lead investor in the issue of units through both subscription commitments and a gratuitous guarantee subscription. The funds from the issue of units is planned to finance the final development stage of the commercial version of the company’s product, NeoNavia® biopsy system, clinical studies to demonstrate the benefits of the technology, marketing and launch. More information about the company and the offer will be presented in the prospectus which will be available on the website of the company (www.neodynamics.com), Sedermera Fondkommission (www.sedermera.se) and Spotlight Stock Market (www.spotlightstockmarket) no later than the day before the start of the subscription period. Nordnet Bank AB is acting as Selling Agent in the issue of units, which will also be marketed in Denmark, Norway and Finland.

About NeoDynamics

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, we have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.

Anna Eriksrud, VD för NeoDynamics, kommenterar

“The most important reason to invest in NeoDynamics, besides the financial potential of NeoNavia, is that we are now part of the battle against cancer. I’m convinced that we can make a difference. I would like to welcome you as an investor to take part in our journey towards providing better care for breast cancer patients. We would like to contribute to better diagnostics methods for the millions of women across the world that are affected by breast cancer every year and thereby provide increased chances of survival.”

Approved for listing

NeoDynamics has been approved for listing at Spotlight. The approval is given under the condition that the company raises the minimum limit of approximately SEK 50.5 million and that the company obtains a sufficient number of shareholders in accordance with Spotlight’s listing agreement. The first day of trading on Spotlight is planned to be the 7th of December 2018.

The issue in summary

Subscription period: October 31 – November 14, 2018.

Issue price: SEK 16.40 per unit. One unit consists of two (2) shares and one (1) associated free warrant of series TO 1. The price per share is thus SEK 8.20.

Subscription post: The minimum subscription post is 375 units, corresponding to SEK 6,150.

Extent of issue: The issue encompasses up to 6,160,000 shares and 3,080,000 series TO 1 warrants, amounting to SEK 50,512,000 and SEK 25,256,000, respectively. The established minimum level for carrying out the issue is 3,080,000 units, amounting to SEK 50,512,000.

Number of shares prior to issue: 9,143,520 shares.

Valuation (pre-money): Approximately SEK 75 million

Subscription commitments and free guarantee subscription: The company has received subscription commitments totalling approximately SEK 29.2 million and a free guarantee subscription (top-down) totalling SEK 6 million, equating to approximately 70 percent of the total issue volume.

Listing on Spotlight: NeoDynamics’ shares and the associated series TO 1 warrants are planned to be listed on Spotlight Stock Market. The planned first day of trading is the 7th of December 2018. The share’s ticker is NEOD.

ISIN code: SE0011563410 for the shares and SE0011725605 for the series TO 1 warrants.

Investor meetings

In connection with the IPO, NeoDynamics will present the business and future plans at a number of investment events. See schedule below for details.

Financial advisor

Sedermera Fondkommission is the financial advisor to NeoDynamics in connection with the issue of units and the planned listing on Spotlight. Nordnet Bank AB is acting as Selling Agent in the issue of units.

For further information about the upcoming IPO and the planned listing, please contact:

Sedermera Fondkommission

Telephone: +46 (0) 40-615 14 10

E-mail: info@sedermera.se

For further information about NeoDynamics, please contact:                           

Anna Eriksrud, CEO NeoDynamics AB (publ)

Telephone: +46 8 522 79 667

E-mail: anna.eriksrud@neodynamics.se

About NeoDynamics

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer. This also increases by an average, increasing  of with about five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, we have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is  currently completing the development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with  with integrating micropulses with incorporating more needle variantsmultiple needle options for maximum versatility.  to enable physicians to handle the majority of all biopsies with micropulse technology. This gives the product the potential to conquer a large part of the biopsy market. The vision is that NeoNavia will be able to replace all the biopsy tools that doctors use today. NeoNavia is expected to be market launchedlaunched  already in Q4towards the end of 2019 and the biopsy system and its technology are expected to get a global breakthrough in a breast biopsy market a market worthof worth approximately USD 500 million per year annually. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.